Provenge Injection
NDC 30237-8900
Product Information
Provenge (sipuleucel-t) is a BLA-approved product labeled by Dendreon Pharmaceuticals Llc. This medication is used to treat advanced prostate cancer. It is supplied as a injection for intravenous administration. This product entry covers the primary NDC 30237-8900 and its associated package configuration. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Clinical Specifications
Labeler & Regulatory Data
Marketing Timeline
Code Structure Chart
Product Details
What is NDC 30237-8900?
What are the uses of this product?
What are Active Ingredients of this product?
- SIPULEUCEL-T 50000000 1/1 - consists of CD54-positive PA2024-loaded antigen presenting cells with admixtures of monocytes, macrophages, and B and T cells; proposed prostate cancer vaccine
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- SIPULEUCEL-T (UNII: 8Q622VDR18)
- SIPULEUCEL-T (UNII: 8Q622VDR18) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- POTASSIUM CHLORIDE (UNII: 660YQ98I10)
- CALCIUM CHLORIDE (UNII: M4I0D6VV5M)
- WATER (UNII: 059QF0KO0R)
- SODIUM CHLORIDE (UNII: 451W47IQ8X)
- SODIUM LACTATE (UNII: TU7HW0W0QT)
What is the NDC to RxNorm Crosswalk for this product?
- RxCUI: 997264 - sipuleucel-T 50,000,000 CELLS in 250 ML Injection
- RxCUI: 997264 - 250 ML sipuleucel-T 200000 CELLS/ML Injection
- RxCUI: 997264 - sipuleucel-T 50,000,000 CELLS per 250 ML Injection
- RxCUI: 997267 - PROVENGE 50,000,000 CELLS in 250 ML Injection
- RxCUI: 997267 - 250 ML sipuleucel-T 200000 CELLS/ML Injection [Provenge]
Which are the Pharmacologic Classes of this product?
* Please review the full disclaimer at the bottom of this page.
Patient Education
Sipuleucel-T Injection
Sipuleucel-T injection is used to treat certain types of advanced prostate cancer. Sipuleucel-T injection is in a class of medications called autologous cellular immunotherapy, a type of medication prepared using cells from the patient's own blood. It works by causing the body's immune system (a group of cells, tissues, and organs that protects the body from attack by bacteria, viruses, cancer cells, and other substances that cause disease) to fight the cancer cells.
[Learn More]
* Please review the full disclaimer at the bottom of this page.